|(A;A)||2||24% chance (lower than average) of docetaxel-induced leukopenia/neutropenia|
|(A;G)||2||63% chance (higher than average) of docetaxel-induced leukopenia/neutropenia|
|(G;G)||(no data; implied high chance of docetaxel-induced leukopenia/neutropenia)|
[PMID 18294295] rs12762549 and rs11045585 can be used to predict whether docetaxel will induce leukopenia/neutropenia, according to a study of ~100 Japanese patients. When patients were classified into three groups by the scoring system based on the genotypes of these two SNPs, patients with a score of 1 or 2 were shown to have a significantly higher risk of docetaxel-induced leukopenia/neutropenia as compared to those with a score of 0 (P = 0.0000057; odds ratio [OR], 7.00; 95% CI [confidence interval], 2.95-16.59). This prediction system correctly classified 69.2% of severe leukopenia/neutropenia and 75.7% of non-leukopenia/neutropenia into the respective categories.
[Effect percentages provided in table are raw population fractions taken from the referenced study based on rs11045585 only. Total population size = 113. Breakdown: leukopenia/neutropenia: AA=20 AG=19; non-leukopenia/neutropenia: AA=63 AG=11]
[PMID 21691256] Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose
[PMID 21468756] The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
[PMID 21673613] The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
[PMID 21829131] The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
[PMID 25648089] Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
[PMID 26475344] CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer